Hepatology
You selected: Hepatology
Increased Mortality Rates Seen in Chronic Hepatitis C Patients with Pre-Cirrhotic Advanced Fibrosis
A three-year follow-up study of patients in the Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) trial revealed that increased mortality among patients with advanced chronic hepatitis C who received long-term peginterferon therapy was attributed to non-liver related causes and occurred primarily in patients with bridging fibrosis. No pattern to this excess mortality was evident to researchers, but deaths were unrelated to the peginterferon treatment. Full findings are published in the April issue of Hepatology, a peer-reviewed journal of the American Association for the Study of Liver Diseases (AASLD).
Sequential Treatment with Entecavir and Lamivudine Results in Rebound of Hepatitis B Virus
A two-year trial of entecavir followed by lamivudine (LAM) in patients with chronic hepatitis B virus (HBV) infection resulted in a virologic rebound rate of 24% and 12% drug-resistance rate. Patients who continued on entecavir therapy throughout the study period had undetectable HBV DNA at the two-year endpoint. Details of this trial are published in the April issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases.
Lack of Health Insurance Limits Hepatitis C Patients’ Access to Latest Antiviral Therapy
New research has determined that patients in the U.S. with hepatitis C virus (HCV) are twice as likely to not have health insurance coverage compared with those without the disease. In fact researchers found only a third of HCV infected Americans have access to antiviral therapy; the remaining are either uninsured or not candidates for therapy due to treatment contraindications. Details of this study are published in the March issue of Hepatology, a peer-reviewed journal of the American Association for the Study of Liver Diseases (AASLD).
Researchers Identify Gene Variants Linked to Hepatitis C Treatment-Related Anemia
In two recent studies, researchers have identified two functional variants in the inosine triphosphatase (ITPA) gene that protect patients with hepatitis C virus (HCV) against anemia brought on by antiviral treatment. The ability to identify those patients protected against treatment-induced anemia will ensure completion of antiviral therapy and successful elimination of the virus. Full findings of these studies appear in the February issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases.
Patients Infected with HIV have Higher Drop-Out Rate for Liver Transplantation
French researchers determined that infection with human immunodeficiency virus (HIV) impaired results of transplant surgery for liver cancer, with more HIV infected patients dropping off the transplantation wait list. The team found that overall survival and recurrence-free survival was not impacted following liver transplantation in patients with controlled HIV disease. Details of this single center study—the largest to date—are published in the February issue of Hepatology, a peer-reviewed journal of the American Association for the Study of Liver Diseases (AASLD).
Liver Cancer in Cirrhotic Patients Effectively Treated with Radiofrequency Ablation
Researchers from Italy determined that radiofrequency ablation (RFA) is a safe and effective therapy for managing hepatocellular carcinoma (HCC) in cirrhotic patients. The high repeatability of RFA is advantageous in controlling recurrences of cancerous tumors in the liver. Results of this 10-year retrospective study are available in the January 2011 issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases (AASLD).
Alcoholics Beware—Genetic Variation Linked to Liver Cirrhosis in Caucasians
A new study by German researchers found that a variation in the PNPLA3 (adiponutrin) gene was associated with cirrhosis of the liver and elevated transaminase (liver enzyme) levels in alcoholic Caucasians. The risk of cirrhosis in alcoholics in the genetic high risk group might be as high as 25 to 50%. Full findings are published in the January 2011 issue of Hepatology, a journal of the American Association for the Study of Liver Diseases.
Scoring System is 93% Accurate for Diagnosing Wilson’s Disease in Pediatric Patients
An Italian research team confirmed that the scoring system for Wilson’s disease (WD) provides good diagnostic accuracy with 93% positive and 92% negative predictive values, respectively in children with mild liver disease. In asymptomatic children, a urinary copper excretion above 40 μg/24 hours was suggestive of WD, however the penicillamine challenge test (PCT) did not provide an accurate diagnosis in this patient subset. Results of the study appear in the December issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases (AASLD).
Study Finds Anti-Microbials a Common Cause of Drug-Induced Liver Injury and Failure
New research shows that anti-microbial medications are a common cause of drug-induced liver injury (DILI) leading to acute liver failure (ALF), with women and minorities disproportionately affected. While ALF evolves slowly, once it does occur a spontaneous recovery is unlikely; however liver transplantation offers an excellent survival rate. Full findings of this ten-year prospective study are published in the December issue of Hepatology, a journal of the American Association for the Study of Liver Diseases.
Visceral Adiposity Index Directly Correlated to Viral Load in Genotype 1 Chronic Hepatitis C
Visceral Adiposity Index Directly Correlated to Viral Load in Genotype 1 Chronic Hepatitis C
Study Finds Adipose Dysfunction Also Linked to Steatosis and Necroinflammation
Adiponectin Shows Potential in Blocking Obesity-Related Carcinogenesis
Adiponectin Shows Potential in Blocking Obesity-Related Carcinogenesis
Protein Hormone Inhibits Leptin-Induced Migration of Liver Cancer Cells
Taribavirin Offers a Safe, Effective Alternative for Chronic Hepatitis C
Weight-based Taribavirin Reduces Anemia, Increases Sustained Virologic Response.
Terlipressin Treatment for Gastrointestinal Bleeding Reduces Serum Sodium
Hyponatremia May Lead to Neurological Complications.
Studies Confirm Genetic Link to Advanced Fatty Liver Disease
Genome-Wide Study Identifies an Important Genetic Variant Associated with NAFLD
Long-term Entecavir Therapy Reverses Fibrosis and Cirrhosis in Chronic Hepatitis B Patients
Substantial Histologic Improvement Achieved in 96% of Patients with Advanced Disease
High Doses of Ursodeoxycholic Acid Ineffective for NASH Patients
A study conducted by researchers at Johann Wolfgang Goethe University in Frankfurt, Germany found that high doses of ursodeoxycholic acid (UDCA), suggested by some studies to have a beneficial effect on nonalcoholic steatohepatitis (NASH), does not improve overall histology in these patients. Full findings of this study are published in the August issue of Hepatology, a journal of the American Association for the Study of Liver Diseases (AASLD).
Depression Overlooked in Patients with Hepatitis C; Compromising HCV Therapy
Lower Patient Productivity and Higher Healthcare Benefit Costs Add to Burden of HCV Infection
Study Finds Poor Compliance with Cirrhosis Surveillance Recommendations
Less than 20% of Qualified Patients Are Regularly Monitored
Study Finds Beta Blockers Alone More Effective for First Variceal Bleeding
Adverse Events Increase When Ligation Is Combined with Nadolol
Antiviral Therapy Impacts Esophageal Varices in HCV-Induced Cirrhosis
Study Shows Sustained Virologic Response Prevents EV


